Expertise in
14
conditions

Dr. Ronald G. Nahass

Infectious Disease
105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
Accepting New Patients
Offers Telehealth
44 Years of Experience
Referral may be required
Before you request
Expertise in
14
conditions
105 Raider Blvd, Suite 101, 
Hillsborough, NJ 

Overview

Ronald Nahass is an Infectious Disease provider practicing medicine in Hillsborough, New Jersey. He has been practicing medicine for over 44 years.

Dr. Nahass is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Hepatitis C, Hepatitis, Hepatitis B, and Lyme Disease.

Dr. Nahass is board certified in American Board Of Internal Medicine, Internal Medicine, 1985, and Infectious Disease, 1988. He is actively involved in clinical research, co-authoring 47 peer reviewed articles and participating in 4 clinical trials. Dr. Nahass is currently accepting new patients.

Graduate Year

1982

Specialties

Infectious Disease

Licenses

Internal Medicine in NJ

Board Certifications

American Board Of Internal Medicine
Internal Medicine, 1985
Infectious Disease, 1988

Fellowships

Robert Wood Johnson University Hospital

Hospital Affiliations

Morristown Medical Center
Robert Wood Johnson University Hospital - Somerset

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

ID Care, Hillsborough
105 Raider Blvd, Suite 101, Hillsborough, NJ 8844.
Other Locations
ID Care
81 Veronica Avenue, Suite 203, Somerset, NJ 08873

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection
Enrollment Status: Completed
Publish Date: April 29, 2026
Intervention Type: Drug
Study Drugs: AB-729, Peg-IFN?-2a
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Current antiretroviral regimen
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

47 Total Publications

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.
Journal: Lancet (London, England)
Published: July 07, 2026
Similar Doctors
Expertise in
43
conditions
Dr. Andrew J. Lee
Infectious Disease
Expertise in
43
conditions
Dr. Andrew J. Lee
Infectious Disease
Referral may be required
Before you request

ID Care, PA

105 Raider Boulevard, Suite 101, 
Hillsborough, NJ 
 (1.5 miles away)
908-281-0221
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Lee is an Infectious Disease provider practicing medicine in Hillsborough, New Jersey. Dr. Lee is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Sepsis, Bacterial Gastroenteritis, Methicillin-Resistant Staphylococcus Aureus (MRSA), Pancreaticoduodenectomy, and Lymphadenectomy. Dr. Lee is currently accepting new patients.

Expertise in
12
conditions
Dr. Jihad S. Slim
Infectious Disease
Expertise in
12
conditions
Dr. Jihad S. Slim
Infectious Disease
Referral may be required

Saint Michael's Medical Center

111 Central Ave, 
Newark, NJ 
 (30.2 miles away)
973-877-5644
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Jihad Slim is an Infectious Disease provider practicing medicine in Newark, New Jersey. Dr. Slim is highly rated in 12 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Hepatitis C, COVID-19, Hepatitis, and Gastrostomy. Dr. Slim is currently accepting new patients.

Expertise in
34
conditions
Dr. David J. Herman
Infectious Disease
Expertise in
34
conditions
Dr. David J. Herman
Infectious Disease
Referral may be required
Before you request

ID Care, Hillsborough

105 Raider Blvd, Suite 101, 
Hillsborough, NJ 
 (0.1 miles away)
609-759-2750
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

David Herman is an Infectious Disease provider practicing medicine in Hillsborough, New Jersey. Dr. Herman is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Sepsis, Bacterial Gastroenteritis, Pneumonia, and Lymphangitis. Dr. Herman is board certified in Internal Medicine, 1988 and Infectious Disease, 1990. Dr. Herman is currently accepting new patients.

Frequently Asked Questions about Dr. Ronald G. Nahass

How do I make an appointment with Dr. Ronald G. Nahass?

You can book an appointment with Dr. Ronald G. Nahass by calling their office at 908-281-0221. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ronald G. Nahass a top-rated expert for Hepatitis C?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ronald G. Nahass is classified as an Distinguished expert for Hepatitis C, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ronald G. Nahass specialize in?

While Dr. Ronald G. Nahass is a Infectious Disease, they have specific expertise in Hepatitis C, Hepatitis, and Hepatitis B. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Ronald G. Nahass participate in research or clinical trials?

Yes. Dr. Ronald G. Nahass has published 47 articles and abstracts on conditions like Hepatitis C. You can view a list of Dr. Ronald G. Nahass's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ronald G. Nahass accept my insurance?

Dr. Ronald G. Nahass accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 908-281-0221 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nahass's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile